GMTX vs. KNSA, ANIP, AKRO, GYRE, MORF, PCRX, DVAX, DAWN, AVDL, and XNCR
Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Kiniksa Pharmaceuticals (KNSA), ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Gyre Therapeutics (GYRE), Morphic (MORF), Pacira BioSciences (PCRX), Dynavax Technologies (DVAX), Day One Biopharmaceuticals (DAWN), Avadel Pharmaceuticals (AVDL), and Xencor (XNCR). These companies are all part of the "pharmaceutical preparations" industry.
Gemini Therapeutics (NASDAQ:GMTX) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.
Kiniksa Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Kiniksa Pharmaceuticals received 147 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 64.34% of users gave Kiniksa Pharmaceuticals an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Gemini Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals' return on equity of -7.26% beat Gemini Therapeutics' return on equity.
75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Kiniksa Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 56.80%. Given Kiniksa Pharmaceuticals' higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Gemini Therapeutics.
In the previous week, Kiniksa Pharmaceuticals had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals and 0 mentions for Gemini Therapeutics. Kiniksa Pharmaceuticals' average media sentiment score of 0.83 beat Gemini Therapeutics' score of 0.00 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.
Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500.
Summary
Kiniksa Pharmaceuticals beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemini Therapeutics Competitors List
Related Companies and Tools
